Přihlásit se Zaregistrujte se zdarma

EBITDA margin společnosti IMV

Jaká je hodnota metriky EBITDA margin společnosti IMV?

Hodnota metriky EBITDA margin společnosti IMV, Inc. je -190,473.91%

Jaká je definice metriky EBITDA margin?



EBITDA margin is a profitability ratio that measures how much EBITDA the company generates as a percentage of revenue.

ttm (trailing twelve months)

EBITDA margin measures how much of EBITDA is generated as a percentage of sales. It measures the company’s operating profit as a percentage of its revenue and is calculated as EBITDA (earnings before interest, taxes, depreciation, and amortization) divided by total revenue.

EBITDA margin also helps with judging the effectiveness of cost-cutting processes at the company. The higher the company’s EBITDA margin, the lower operating expenses are in respect to revenue. As a result, a higher EBITDA margin is considered more favorable. Smaller companies can have higher EBITDA margins since they are able to operate more efficiently and maximize their profitability.

EBITDA excludes interest on debt, taxes, and capital expenditures, the margin does not provide a perfectly clear estimate of the business’s cash flow generation. Furthermore, EBITDA margin is not recognized as a GAAP (generally accepted accounting principles) metric.

EBITDA margin společností v sektoru Health Care sektor na TSX ve srovnání se společností IMV

Čemu se věnuje společnost IMV?

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

Firmy s metrikou ebitda margin podobnou společnosti IMV



  • Hodnota metriky EBITDA margin společnosti Hannans je -217,102.01%
  • Hodnota metriky EBITDA margin společnosti Laramide Resources je -215,666.29%
  • Hodnota metriky EBITDA margin společnosti Indosolar je -213,170.97%
  • Hodnota metriky EBITDA margin společnosti Torrens Mining je -209,180.39%
  • Hodnota metriky EBITDA margin společnosti Roadman Investments je -198,529.94%
  • Hodnota metriky EBITDA margin společnosti Gett Gold Inc je -195,481.64%
  • Hodnota metriky EBITDA margin společnosti IMV je -190,473.91%
  • Hodnota metriky EBITDA margin společnosti Graphex Mining je -188,798.26%
  • Hodnota metriky EBITDA margin společnosti ProMIS Neurosciences je -175,931.75%
  • Hodnota metriky EBITDA margin společnosti Auroch Minerals je -172,893.76%
  • Hodnota metriky EBITDA margin společnosti Peak Resources je -170,548.84%
  • Hodnota metriky EBITDA margin společnosti Property Connect je -163,310.80%
  • Hodnota metriky EBITDA margin společnosti IPB Petroleum je -155,607.53%